BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine

Trial Profile

BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine

Recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Apr 2018

At a glance

  • Drugs Rimegepant (Primary)
  • Indications Migraine
  • Focus Registrational; Therapeutic Use
  • Sponsors Biohaven Pharmaceutical Holding Company
  • Most Recent Events

    • 27 Mar 2018 Planned primary completion date changed from 28 May 2018 to 3 Aug 2018.
    • 06 Mar 2018 According to a Biohaven Pharmaceutical Holding Company media release, the company expects this study to complete in the fourth quarter of 2018.
    • 06 Mar 2018 According to a Biohaven Pharmaceutical Holding Company media release, the company expects topline results from this phase 3 trial with rimegepant Zydis ODT in the fourth quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top